Catalent Pharma Solutions has acquired the remaining stake in Redwood Bioscience Inc., along with the SMARTag Antibody-Drug Conjugate (ADC) technology platform. The acquisition is part of Catalent’s strategy to add differentiated technology and to strengthen its position in the biologics market.   The acquisition follows successful in vivo and in vitro proof of concept milestones providing compelling in vivo toxicology data and strong customer interest in the SMARTag technology. Redwood’s team i...